Drug
AMDX-2011P
AMDX-2011P is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
3
75%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
completed125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
A Study of AMDX-2011P in Participants With CAA
NCT05709314
recruitingphase_2
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001
completedphase_1
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
NCT05542576
recruitingphase_2
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
NCT06223048
Clinical Trials (4)
Showing 4 of 4 trials
NCT05709314Phase 2
A Study of AMDX-2011P in Participants With CAA
NCT06514001Phase 2
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT05542576Phase 1
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
NCT06223048Phase 2
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4